Exhibit  99.1


NEWS  RELEASE                                 FOR  IMMEDIATE  RELEASE

For Further Information Contact:
Steven  T.  Sobieski                          Kevin  McGrath
Chief  Financial  Officer                     Cameron  Associates
(908)  947-1106                               (212)  245-8800
ssobieski@lifecell.com                        kevin@cameronassoc.com


                LIFECELL ANNOUNCES $14 MILLION PRIVATE PLACEMENT

                 OF COMMON STOCK LEAD BY WELLS FARGO SECURITIES


BRANCHBURG,  N.J.,  AUGUST  11,  2003  -- LifeCell Corporation (NASDAQ: LIFC), a
                                                                        ----
leader  in  tissue  regeneration,  announced  today  that  it  has  entered into
definitive  purchase  agreements with a group of institutional investors for the
private  placement of 3,294,000 newly issued shares of common stock at $4.25 per
share,  or  an  aggregate  purchase  price of  $14 million.  No warrants will be
issued  in  connection with the transaction.  The financing is expected to close
this  week  and  is  contingent  upon certain customary closing conditions.  The
Company  may  issue  up  to  an  additional  400,000 shares on the same terms if
certain  holders  of the Company's Series B Preferred Stock exercise their right
to  participate  in the placement.  Wells Fargo Securities, LLC and Roth Capital
Partners,  LLC  served  as  placement  agents  for  the  transaction.

"Net  proceeds  from  the financing will be used to continue product development
programs,  expand  sales  and  marketing  and  for  potential  acquisitions  of
complementary  technologies  or products," said Paul Thomas, President and Chief
Executive  Officer  of  LifeCell.

ABOUT  LIFECELL
---------------

LifeCell  is  a  leader  in  tissue  regeneration  through  the  development and
commercialization  of  biological  products  for  the  repair and replacement of
damaged  or inadequate human tissue in numerous different clinical applications.
The  Company's  patented tissue processing methods produce a unique regenerative
tissue  matrix  -  a complex three dimensional structure that contains proteins,
growth factors and vascular channels - that provides a complete template for the
regeneration  of  normal human tissue.  LifeCell currently markets a broad range
of products:  AlloDerm(R), regenerative tissue matrix for skin grafting for burn
and  cancer  patients  and  for  reconstructive  surgical  procedures,  through
LifeCell's  direct  sales  organization,  and  for  periodontal  surgery through
BioHorizons,  Inc.;  Repliform(R),  regenerative  tissue matrix for urologic and
gynecologic  procedures,  through  a  marketing agreement with Boston Scientific
Corporation;  Cymetra(R),  a  version  of  AlloDerm  in particulate form for the
correction  of soft tissue defects, through LifeCell's direct sales organization
and  a co-promotion agreement with OMP, Inc.; and Graft Jacket(TM), regenerative
tissue matrix for orthopedic applications, through a distribution agreement with
Wright  Medical  Technology,  Inc.  The  Company is also the exclusive marketing
agent  for  the SmartPReP(TM) Platelet Concentration System in the United States
to  ear,  nose  and  throat,  plastic  reconstructive  and  general  surgeons in
hospitals.  The  Company's  ongoing  product  development  programs  include the
application  of  its  tissue matrix technology to vascular, nerve and orthopedic
tissue  repair;  investigation  of  human  tissues as carriers for therapeutics;
Thrombosol(TM), a



formulation  for  extended  storage of platelets and technologies to enhance the
storage  of  red  blood  cells  for  transfusion.  Visit the LifeCell website at
www.lifecell.com.
----------------

                                     -more-

This  release  contains  forward-looking  statements  made  pursuant to the safe
harbor  provisions of the Private Securities Litigation Reform Act of 1995, such
as  the  Company's  ability to develop and market new products, expand sales and
marketing  and  acquire complementary technologies or products.  Forward-looking
statements  represent  management's  judgment regarding future events.  Although
management  believes  that  the  expectations  reflected  in such statements are
reasonable,  they  give  no  assurance  that  such expectations will prove to be
correct and you should be aware that actual results could differ materially from
those  contained  in  the forward-looking statements due to a number of factors.
These  factors include the risks detailed in the Company's Reports as filed with
the  Securities  and  Exchange  Commission.



                                    - ### -